Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study.

PubWeight™: 1.92‹?› | Rank: Top 3%

🔗 View Article (PMID 90802)

Published in Lancet on October 06, 1979

Authors

T A Hutchinson, S M Polansky, A R Feinstein

Articles citing this

Strategies for prevention of osteoporosis and hip fracture. BMJ (1991) 3.78

Race and sex differences in hip fracture incidence. Am J Public Health (1984) 3.07

Calcium supplementation of the diet--II. BMJ (1989) 1.85

Reducing the threat of hip fracture. Am J Public Health (1989) 1.40

The risk of hip fracture in postmenopausal females with or without estrogen drug exposure. Am J Public Health (1981) 1.21

Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut (1993) 1.17

Osteoporosis management in long-term care. Survey of Ontario physicians. Can Fam Physician (2000) 1.14

Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. J Clin Endocrinol Metab (2010) 1.09

Risk factors for hip fracture in US men aged 40 through 75 years. Am J Public Health (1994) 1.02

Osteoporosis: Part II. Prevention of Bone Loss and Fractures in Women and Risks of Menopausal Estrogen Therapy. West J Med (1983) 1.01

Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br J Cancer (1996) 0.94

Risk factors, falls, and fracture of the distal forearm in Manchester, UK. J Epidemiol Community Health (1996) 0.94

The epidemiology of hip fracture in Asia: an update. Osteoporos Int (1996) 0.93

The periodic health examination: 2. 1987 update. Canadian Task Force on the Periodic Health Examination. CMAJ (1988) 0.91

Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice. J Bone Miner Metab (2009) 0.89

Hormone replacement therapy in general practice. BMJ (1991) 0.88

Hip fracture, skeletal fragility, osteoporosis and hormonal deprivation in elderly women. West J Med (1980) 0.88

Fractures and lifestyle: effect of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-aged women. Am J Public Health (1988) 0.85

Reproductive factors and fatal hip fractures. A Norwegian prospective study of 63,000 women. J Epidemiol Community Health (1998) 0.83

Endogenous sex hormones and bone mineral density among community-based postmenopausal women. Postgrad Med J (1992) 0.83

Lens opacities in women in Beaver Dam, Wisconsin: is there evidence of an effect of sex hormones? Trans Am Ophthalmol Soc (1993) 0.82

Estrogens and endometrial cancer: some answers and some further questions. Can Med Assoc J (1981) 0.81

Classic yin and yang tonic formula for osteopenia: study protocol for a randomized controlled trial. Trials (2011) 0.81

Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group. Osteoporos Int (1997) 0.81

Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy. Calcif Tissue Int (1991) 0.80

Risk factors for osteoporosis and associated fractures. Public Health Rep (1990) 0.80

That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention. Ann Rheum Dis (1993) 0.78

Population screening for osteoporosis to prevent fractures. Qual Health Care (1992) 0.78

Estrogen: effects and actions in osteoporosis. Osteoporos Int (1993) 0.78

The menopause and hormone replacement therapy. Postgrad Med J (1992) 0.77

Understanding osteoporosis. West J Med (1991) 0.76

Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study. Osteoporos Int (2004) 0.76

Oestrogen-replacement treatment in old age. Br Med J (1980) 0.75

Postmenopausal osteoporosis. Br Med J (Clin Res Ed) (1982) 0.75

Estrogen replacement therapy (ERT) in high-risk cancer patients. Yale J Biol Med (1992) 0.75

Estrogen replacement therapy for postmenopausal osteoporosis. Can Fam Physician (1986) 0.75

[Not Available]. Can Fam Physician (1983) 0.75

The menopause. West J Med (1982) 0.75

Late prevention of hip fractures with hormone replacement therapy. Osteoporos Int (1996) 0.75

Glycitein decreases the generation of murine osteoclasts and increases apoptosis. Wien Med Wochenschr (2010) 0.75

Articles by these authors

A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol (1996) 20.25

Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med (1978) 11.42

A critical appraisal of the quality of quality-of-life measurements. JAMA (1994) 9.10

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55

High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol (1990) 8.28

Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther (1981) 7.33

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol (1995) 6.94

The risk of determining risk with multivariable models. Ann Intern Med (1993) 6.45

Variability in radiologists' interpretations of mammograms. N Engl J Med (1994) 5.96

Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA (1995) 5.94

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19

Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med (1992) 3.64

Academic calculations versus clinical judgments: practicing physicians' use of quantitative measures of test accuracy. Am J Med (1998) 3.36

Problems of comorbidity in mortality after prostatectomy. JAMA (1992) 3.27

Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA (1999) 3.07

An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA (1979) 3.03

The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis (1974) 3.01

The BCG controversy. A methodological and statistical reappraisal. JAMA (1983) 2.60

Clinical biostatistics. XXXVII. Demeaned errors, confidence games, nonplussed minuses, inefficient coefficients, and other statistical disruptions of scientific communication. Clin Pharmacol Ther (1976) 2.53

An analysis of diagnostic reasoning. 3. The construction of clinical algorithms. Yale J Biol Med (1974) 2.44

Context bias. A problem in diagnostic radiology. JAMA (1996) 2.42

Scientific and clinical problems in indexes of functional disability. Ann Intern Med (1986) 2.41

The qualification period. J Clin Epidemiol (1991) 2.33

Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol (1995) 2.32

A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med (1990) 2.32

Clinical biostatistics. 8. An analytic appraisal of the University Group Diabetes Program (UGDP) study. Clin Pharmacol Ther (1971) 2.28

Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med (2000) 2.27

Coding ordinal independent variables in multiple regression analyses. Am J Epidemiol (1987) 2.15

A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med (1989) 2.10

Methodologic standards and contradictory results in case-control research. Am J Med (1979) 2.09

Clinical biostatistics. XLIV. A survey of the research architecture used for publications in general medical journals. Clin Pharmacol Ther (1978) 2.07

T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. Circulation (1982) 2.06

Clinical biostatistics. XLI. Hard science, soft data, and the challenges of choosing clinical variables in research. Clin Pharmacol Ther (1977) 2.04

A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol (1988) 2.02

The impact of ethnicity, family income, and parental education on children's health and use of health services. Am J Public Health (1999) 2.02

A new clinical prognostic staging system for acute pancreatitis. Am J Med (1993) 2.02

The 'chagrin factor' and qualitative decision analysis. Arch Intern Med (1985) 1.94

An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med (1983) 1.87

Clinical biostatistics. XXV. A survey of the statistical procedures in general medical journals. Clin Pharmacol Ther (1974) 1.87

Double standards, scientific methods, and epidemiologic research. N Engl J Med (1982) 1.81

Clinical biostatistics. XXXIX. The haze of Bayes, the aerial palaces of decision analysis, and the computerized Ouija board. Clin Pharmacol Ther (1977) 1.80

An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA (1979) 1.65

Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol (1990) 1.63

Measurement of lower limb alignment using long radiographs. J Bone Joint Surg Br (1991) 1.58

Current problems and future challenges in randomized clinical trials. Circulation (1984) 1.57

An analysis of Berkson's bias in case-control studies. J Chronic Dis (1986) 1.53

Clinical biostatistics XXXI. On the sensitivity, specificity, and discrimination of diagnostic tests. Clin Pharmacol Ther (1975) 1.52

Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis (1970) 1.51

The problems of the "problem-oriented medical record". Ann Intern Med (1973) 1.50

Complications of peripheral arteriography: a new system to identify patients at increased risk. J Vasc Surg (1995) 1.50

Clinical biostatistics. XX. The epidemiologic trohoc, the ablative risk ratio, and "retrospective" research. Clin Pharmacol Ther (1973) 1.50

The role of diagnostic inconsistency in changing rates of occurrence for coronary heart disease. J Clin Epidemiol (1992) 1.50

On white-coat effects and the electronic monitoring of compliance. Arch Intern Med (1990) 1.48

Joseph Goldberger: an unsung hero of American clinical epidemiology. Ann Intern Med (1994) 1.47

A bibliography of publications on observer variability (final installment). J Clin Epidemiol (1992) 1.47

An analysis of diagnostic reasoning. I. The domains and disorders of clinical macrobiology. Yale J Biol Med (1973) 1.47

Clinical utility of endoscopic retrograde cholangiopancreatography. Gastrointest Endosc (1997) 1.45

Bootstraps and jackknives: new, computer-intensive statistical tools that require no mathematical theories. J Investig Med (1998) 1.43

An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med (1983) 1.43

Discontinuation of antistreptococcal prophylaxis. A double-blind study in rheumatic patients free of heart disease. JAMA (1966) 1.42

A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med (1969) 1.42

The problem of "protopathic bias" in case-control studies. Am J Med (1980) 1.41

A study on intrauterine fetal resuscitation with terbutaline. Am J Obstet Gynecol (1987) 1.40

On exorcizing the ghost of Gauss and the curse of Kelvin. MD Comput (1992) 1.39

Coffee and pancreatic cancer. The problems of etiologic science and epidemiologic case-control research. JAMA (1981) 1.37

Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis (1986) 1.36

Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size. Clin Pharmacol Ther (1975) 1.36

The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer. JAMA (1987) 1.35

Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis (1979) 1.34

New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA (1989) 1.34

Patients' perceptions of their experiences with ESRD and hemodialysis treatment. Qual Health Res (1998) 1.31

Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer (1996) 1.31

An additional basic science for clinical medicine: I. The constraining fundamental paradigms. Ann Intern Med (1983) 1.29

Clinical effects of recurrent attacks of acute rheumatic fever: a prospective epidemiologic study of 105 episodes. J Chronic Dis (1967) 1.28

Monte Carlo methods in clinical research: applications in multivariable analysis. J Investig Med (1997) 1.28

Interobserver agreement by auscultation in the presence of a third heart sound in patients with congestive heart failure. Chest (1987) 1.27

Operational criteria for adverse drug reactions in evaluating suspected toxicity of a popular scabicide. Clin Pharmacol Ther (1980) 1.27

Clinical biostatistics. XXVII. The derangements of the 'range of normal'. Clin Pharmacol Ther (1974) 1.27

Clinical biostatistics. II. Statistics versus science in design of experiments. Clin Pharmacol Ther (1970) 1.27

Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance. Clin Pharmacol Ther (1974) 1.26

What kind of basic science for clinical medicine? N Engl J Med (1970) 1.25

Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med (1978) 1.25

The emotional impact of end-stage renal disease: importance of patients' perception of intrusiveness and control. Int J Psychiatry Med (1984) 1.23

Ask patients what they want. Evaluation of individual complaints before total hip replacement. J Bone Joint Surg Br (1994) 1.23

Invidious comparisons and unmet clinical challenges. Am J Med (1992) 1.22

Necropsy evidence of detection bias in the diagnosis of lung cancer. Arch Intern Med (1986) 1.21

The need for humanised science in evaluating medication. Lancet (1972) 1.21

Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol (1990) 1.20

Symptoms as an index of biological behaviour and prognosis in human cancer. Nature (1966) 1.20

Adverse drug reactions in general pediatric outpatients. J Pediatr (1985) 1.20

The impact of clinical history on mammographic interpretations. JAMA (1997) 1.17

The role of tonsils in predisposing to streptococcal infections and recurrences of rheumatic fever. N Engl J Med (1970) 1.17

A bibliography of publications on observer variability. J Chronic Dis (1985) 1.17

The auxometric dimension. A new method for using rate of growth in prognostic staging of breast cancer. JAMA (1974) 1.17

A reappraisal of histopathology in lung cancer and correlation of cell types with antecedent cigarette smoking. Am Rev Respir Dis (1973) 1.17

Taxonorics. I. Formulation of criteria. Arch Intern Med (1970) 1.16